Author: Ravi Shankar

THE WOODLANDS, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — TWFG, Inc. (NASDAQ: TWFG), a leading independent insurance distribution platform, announced today that it will release its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.

The Company will host a conference call to discuss its financial results at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Wednesday, November 4, 2026.

CLICK HERE TO ACCESS THE CALL BY WEBCAST

TO REGISTER FOR ACCESS TO THE LIVE CONFERENCE CALL:

• Click on the link below and complete the online registration form.
• Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
• Select a method for joining the call:
• Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
• Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.

CLICK HERE TO REGISTER

A replay of the webcast will be available on the Investor Relations website for a limited time following the call.

About TWFG

TWFG, Inc. (NASDAQ: TWFG) is a leading insurance distribution platform providing innovative and personalized insurance solutions to individuals and businesses across the United States. Anchored by a scalable, technology-enabled platform, TWFG supports a sophisticated agent network of retail branch agencies, and MGA agents, that create sustainable growth and long-term value. For more information, visit www.twfg.com.

For more information, please contact:

Investor Contact:
ir@twfg.com

PR Contact:
Alex Bunch
TWFG, Inc. – Chief Marketing Officer
E-mail: alex@twfg.com

THE WOODLANDS, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — TWFG, Inc. (NASDAQ: TWFG), a leading independent insurance distribution platform, announced today that it will release its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.

The Company will host a conference call to discuss its financial results at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Wednesday, November 4, 2026.

CLICK HERE TO ACCESS THE CALL BY WEBCAST

TO REGISTER FOR ACCESS TO THE LIVE CONFERENCE CALL:

• Click on the link below and complete the online registration form.
• Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
• Select a method for joining the call:
• Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
• Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.

CLICK HERE TO REGISTER

A replay of the webcast will be available on the Investor Relations website for a limited time following the call.

About TWFG

TWFG, Inc. (NASDAQ: TWFG) is a leading insurance distribution platform providing innovative and personalized insurance solutions to individuals and businesses across the United States. Anchored by a scalable, technology-enabled platform, TWFG supports a sophisticated agent network of retail branch agencies, and MGA agents, that create sustainable growth and long-term value. For more information, visit www.twfg.com.

For more information, please contact:

Investor Contact:
ir@twfg.com

PR Contact:
Alex Bunch
TWFG, Inc. – Chief Marketing Officer
E-mail: alex@twfg.com

ITHACA, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) — Commercial National Financial Corporation (OTCID: CEFC) reported net income of $1,721,000 or $0.44 per share for the third quarter of 2026 compared to $1,791,000 or $0.45 per share for the third quarter of 2025. Return on Equity was 12.00% for the third quarter of 2026 compared to 13.35% for the third quarter of 2025.

Net interest income for the third quarter of 2026 increased by $124,000 or 2.4% compared to the respective 2025 period. Interest income increased by $36,000, mainly due to an increase in securities. Interest expense decreased by $88,000, mainly due to a decrease in funding costs. Non-interest income slightly decreased by $16,000, while operating expenses increased by $192,000, which was mainly due to higher wages and benefits expense.

Total assets were $565 million as of September 30, 2026 compared to $548 million as of September 30, 2025. Total securities grew by $40 million, which was financed through a strategic combination of excess cash, new wholesale borrowings, and liquidity from loan payoffs. While total deposits increased by $7 million, there was a shift towards wholesale funding, as brokered deposits increased by $20 million, which helped offset a $13 million decrease in core deposits. To further support balance sheet growth, Federal Home Loan Bank borrowings were increased by $10 million. While total loans decreased by $10 million or 2.7% due to the high interest rate environment and early loan payoffs, loan quality remained strong with a non-performing assets ratio of 0.25%. Additionally, CEFC’s wholly owned subsidiary, Commercial Bank, remained “well capitalized” for regulatory purposes.

CEFC announced a share repurchase program in May of 2025, which remains in effect indefinitely. As of September 30, 2026, CEFC has repurchased 91,333 shares since the inception of the repurchase program and has allocated an additional $1.2 million for future share repurchases. CEFC may repurchase shares under the program at its discretion, taking into account factors such as the share price, market conditions, share availability, and other relevant considerations. There is no guarantee that any specific number of shares will be repurchased, and CEFC may modify, renew, suspend, or terminate the program at any time without prior notice. For further information about the stock repurchase program, please contact our primary market maker, Nick Bicking at Brean Capital, LLC, at 614-638-4584.

Visit www.commercial-bank.com to view the latest news releases and other information about CEFC and Commercial Bank.

Selected Financial Data (unaudited):
		Quarter Ended							Year to Date
		Sep 30, 2026				Sep 30, 2025			Sep 30, 2026			Sep 30, 2025
Return on equity		12.00	%			13.35	%		11.82	%		12.36	%
Return on assets		1.22	%			1.30	%		1.21	%		1.16	%
Net interest margin		4.01	%			3.97	%		3.99	%		3.82	%
		Sep 30, 2026				Sep 30, 2025
Non-performing assets ratio		0.25	%			0.26	%
Tier 1 leverage capital ratio(1)		10.79	%			10.86	%
Total risk-based capital ratio(1)		18.34	%			17.75	%
Book value per share	$	14.09			$	13.90
Market value per share	$	16.00			$	12.10
Common shares outstanding		3,873,970				3,936,200
(1) Ratios are for Commercial Bank

Consolidated Statements of Income (unaudited):
	Quarter Ended								Year to Date
	Sep 30, 2026				Sep 30, 2025				Sep 30, 2026				Sep 30, 2025
Interest income	$	6,604,025			$	6,567,747			$	19,454,745			$	19,584,846
Interest expense		1,343,035				1,430,850				3,880,544				4,630,286
Net interest income		5,260,990				5,136,897				15,574,201				14,954,560
Provision for credit losses		695				(22,241	)			(45,647	)			(56,454	)
Non-interest income		550,842				566,870				1,683,713				1,579,482
Operating expenses		3,728,675				3,536,970				11,179,445				10,709,151
Income before taxes		2,082,462				2,189,038				6,124,116				5,881,345
Income tax expense		361,700				398,025				1,085,400				1,053,975
Net income	$	1,720,762			$	1,791,013			$	5,038,716			$	4,827,370
Basic earnings per share	$	0.44			$	0.45			$	1.29			$	1.22
Diluted earnings per share	$	0.44			$	0.45			$	1.29			$	1.22
Dividends declared	$	0.15			$	0.14			$	0.45			$	0.42
Weighted-average common shares outstanding		3,877,705				3,944,782				3,900,592				3,958,387
Number of shares repurchased		3,819				29,103				62,230				29,103

Consolidated Balance Sheets (unaudited):
	Sep 30, 2026				Sep 30, 2025
Assets
Cash and cash equivalents	$	37,645,032			$	50,432,608
Time deposits with other banks		–				1,494,000
Securities		127,362,290				87,151,048
Loans		367,330,815				377,670,851
Allowance for credit losses		(3,328,428	)			(3,413,163	)
Loans, net		364,002,387				374,257,688
Premises and equipment, net		9,708,869				9,732,492
Other assets		26,003,285				24,647,796
Total assets	$	564,721,863			$	547,715,632
Liabilities
Deposits	$	488,263,811			$	481,103,001
FHLB borrowings		11,000,000				1,000,000
Trust preferred		7,310,000				7,310,000
Other liabilities		3,550,725				3,605,711
Total liabilities		510,124,536				493,018,712
Equity
Total equity		54,597,327				54,696,920
Total liabilities and equity	$	564,721,863			$	547,715,632

Contact:
Benjamin Ogle
CFO
989-875-5562

This press release was published by a CLEAR® Verified individual.

ITHACA, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) — Commercial National Financial Corporation (OTCID: CEFC) reported net income of $1,721,000 or $0.44 per share for the third quarter of 2026 compared to $1,791,000 or $0.45 per share for the third quarter of 2025. Return on Equity was 12.00% for the third quarter of 2026 compared to 13.35% for the third quarter of 2025.

Net interest income for the third quarter of 2026 increased by $124,000 or 2.4% compared to the respective 2025 period. Interest income increased by $36,000, mainly due to an increase in securities. Interest expense decreased by $88,000, mainly due to a decrease in funding costs. Non-interest income slightly decreased by $16,000, while operating expenses increased by $192,000, which was mainly due to higher wages and benefits expense.

Total assets were $565 million as of September 30, 2026 compared to $548 million as of September 30, 2025. Total securities grew by $40 million, which was financed through a strategic combination of excess cash, new wholesale borrowings, and liquidity from loan payoffs. While total deposits increased by $7 million, there was a shift towards wholesale funding, as brokered deposits increased by $20 million, which helped offset a $13 million decrease in core deposits. To further support balance sheet growth, Federal Home Loan Bank borrowings were increased by $10 million. While total loans decreased by $10 million or 2.7% due to the high interest rate environment and early loan payoffs, loan quality remained strong with a non-performing assets ratio of 0.25%. Additionally, CEFC’s wholly owned subsidiary, Commercial Bank, remained “well capitalized” for regulatory purposes.

CEFC announced a share repurchase program in May of 2025, which remains in effect indefinitely. As of September 30, 2026, CEFC has repurchased 91,333 shares since the inception of the repurchase program and has allocated an additional $1.2 million for future share repurchases. CEFC may repurchase shares under the program at its discretion, taking into account factors such as the share price, market conditions, share availability, and other relevant considerations. There is no guarantee that any specific number of shares will be repurchased, and CEFC may modify, renew, suspend, or terminate the program at any time without prior notice. For further information about the stock repurchase program, please contact our primary market maker, Nick Bicking at Brean Capital, LLC, at 614-638-4584.

Visit www.commercial-bank.com to view the latest news releases and other information about CEFC and Commercial Bank.

Selected Financial Data (unaudited):
		Quarter Ended							Year to Date
		Sep 30, 2026				Sep 30, 2025			Sep 30, 2026			Sep 30, 2025
Return on equity		12.00	%			13.35	%		11.82	%		12.36	%
Return on assets		1.22	%			1.30	%		1.21	%		1.16	%
Net interest margin		4.01	%			3.97	%		3.99	%		3.82	%
		Sep 30, 2026				Sep 30, 2025
Non-performing assets ratio		0.25	%			0.26	%
Tier 1 leverage capital ratio(1)		10.79	%			10.86	%
Total risk-based capital ratio(1)		18.34	%			17.75	%
Book value per share	$	14.09			$	13.90
Market value per share	$	16.00			$	12.10
Common shares outstanding		3,873,970				3,936,200
(1) Ratios are for Commercial Bank

Consolidated Statements of Income (unaudited):
	Quarter Ended								Year to Date
	Sep 30, 2026				Sep 30, 2025				Sep 30, 2026				Sep 30, 2025
Interest income	$	6,604,025			$	6,567,747			$	19,454,745			$	19,584,846
Interest expense		1,343,035				1,430,850				3,880,544				4,630,286
Net interest income		5,260,990				5,136,897				15,574,201				14,954,560
Provision for credit losses		695				(22,241	)			(45,647	)			(56,454	)
Non-interest income		550,842				566,870				1,683,713				1,579,482
Operating expenses		3,728,675				3,536,970				11,179,445				10,709,151
Income before taxes		2,082,462				2,189,038				6,124,116				5,881,345
Income tax expense		361,700				398,025				1,085,400				1,053,975
Net income	$	1,720,762			$	1,791,013			$	5,038,716			$	4,827,370
Basic earnings per share	$	0.44			$	0.45			$	1.29			$	1.22
Diluted earnings per share	$	0.44			$	0.45			$	1.29			$	1.22
Dividends declared	$	0.15			$	0.14			$	0.45			$	0.42
Weighted-average common shares outstanding		3,877,705				3,944,782				3,900,592				3,958,387
Number of shares repurchased		3,819				29,103				62,230				29,103

Consolidated Balance Sheets (unaudited):
	Sep 30, 2026				Sep 30, 2025
Assets
Cash and cash equivalents	$	37,645,032			$	50,432,608
Time deposits with other banks		–				1,494,000
Securities		127,362,290				87,151,048
Loans		367,330,815				377,670,851
Allowance for credit losses		(3,328,428	)			(3,413,163	)
Loans, net		364,002,387				374,257,688
Premises and equipment, net		9,708,869				9,732,492
Other assets		26,003,285				24,647,796
Total assets	$	564,721,863			$	547,715,632
Liabilities
Deposits	$	488,263,811			$	481,103,001
FHLB borrowings		11,000,000				1,000,000
Trust preferred		7,310,000				7,310,000
Other liabilities		3,550,725				3,605,711
Total liabilities		510,124,536				493,018,712
Equity
Total equity		54,597,327				54,696,920
Total liabilities and equity	$	564,721,863			$	547,715,632

Contact:
Benjamin Ogle
CFO
989-875-5562

This press release was published by a CLEAR® Verified individual.

Perth, Western Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) —                                                                     

SEPTEMBER 2026 QUARTER REPORT

Perseus delivers another strong quarter, ending with cash & bullion of US$900 million

Perth, Western Australia/ October 27, 2026/ Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended on September 30, 2026 (the “Quarter”). Below is a summary of the release. The full report is available at www.perseusmining.com www.sedarplus.ca and www.asx.com.au

Overview

• Group TRIFR 1.01 with Nyanzaga Gold Project (NGP) achieving 10.9 million worked hours LTI free
• Q1 FY27 Group production exceeds plan with 92,551 ounces of gold at an All-In Site Costs (AISC) of US$2,035 per ounce
• Average cash margin of US$1,846/oz of gold produced, delivering notional operating cashflow of US$171 million
• Yaouré CMA Underground achieves commercial production
• NGP reached 88.4% overall project progress, and development remains on track for first production by January 2027
• Cash and bullion of US$900 million, plus liquid listed securities valued at US$338 million

FY27 Outlook

With production plans exceeded for Q1 FY27, Perseus remains on track for production and AISC guidance for June 2027 Financial Year (FY27) of 420,000 – 480,000 ounces at US$1,835 – 2,070 per ounce.

Key operating indicators and highlights for the September 2026 quarter (Q1 FY27) include:

Table 1: Group Quarterly Performance

PERFORMANCE INDICATOR	UNIT	DECEMBER 2025 QUARTER	MARCH 2026  QUARTER	JUNE 2026  QUARTER	SEPTEMBER 2026  QUARTER3
Gold recovered	Ounces	88,8881	107,1441	109,0131	92,551
Production Cost	US$/ounce	1,3622	1,2382	1,3402	1,472
All-In Site Cost (AISC)	US$/ounce	1,8002	1,7482	1,9412	2,035
All in Sustaining Cost	US$/ounce	1,8972	1,6042	1,8482	1,855
Gold sales	Ounces	86,6071	96,2601	114,5671	99,661
Average sales price	US$/ounce	3,4372	4,1432	4,0862	3,881
Notional Cashflow	US$ million	1452	2522	2162	171

1. Includes the CMA Underground gold produced and sold for the quarter before commercial production was achieved. Commercial production for CMA Underground was achieved on 1 July 2026.  
2. Excludes CMA Underground production cost, gold produced, AISC, Average sales price and Notional Cashflow as the related cash costs are capitalised until commercial production was achieved.
3. All metrics include CMA Underground following commercial production achieved on 1 July 2026.

Perseus’s Managing Director and CEO Craig Jones said:

“The September Quarter was a solid start to FY27, with all three operations performing and on track for our full year guidance. The CMA Underground has achieved commercial production and our Nyanzaga project is progressing to completion with an outstanding safety record, remaining on budget and on schedule. Our balance sheet remains strong and debt-free, to fund our growth objectives while continuing to deliver meaningful returns to shareholders through our buy-back and the upcoming Special Distribution. I want to thank our employees and contractors for their continued commitment across our sites.

Looking ahead, we expect production to build through the second half of the year as Yaouré’s CMA continues to increase production and Edikan accesses higher grades in the Nkosuo pit along with Nyanzaga commencing operation, positioning Perseus for a transformational year”.

Conference Call Perseus will host investor webinar and conference call to discuss its September 2026 Quarterly Results, at 9.00am AEDT today (27 October 2026). Register for the webinar at:
https://us02web.zoom.us/webinar/register/WN_5JPqtLq5QVOV1wqjG1Mn1g

A recording of the conference call will be made available via Perseus’s website at www.perseusmining.com.

GROUP GOLD PRODUCTION AND COST GUIDANCE

Perseus remains on track to deliver group gold production and AISC for the 2027 financial year as shown in Table 6 below.

Table 6: Production and AISC Guidance

PARAMETER	UNITS	SEPTEMBER 2026  QUARTER (ACTUAL)		2027 FINANCIAL YEAR FORECAST
Yaouré Gold Mine
Production	Ounces		36,648	150,000 – 170,000
All-in Site Cost (1)	US$ per ounce	$	2,393	$1,955 – $2,205
Edikan Gold Mine
Production	Ounces		35,830	150,000 – 170,000
All-in Site Cost (1)	US$ per ounce	$	1,738	$1,700 – $1,920
Sissingué Gold Mine
Production	Ounces		20,073	65,000 – 85,000
All-in Site Cost (1)	US$ per 0unce	$	1,913	$1,865 – $2,105
Nyanzaga Gold Mine
Production (2)	Ounces		–	~55,000
PERSEUS GROUP
Production	Ounces		92,551	420,000 – 480,000
All-in Site Cost (1)	US$ per ounce	$	2,035	$1,835 – $2,070

Notes

1. Cost guidance is based on a gold price assumption of $4,000 per ounce and Government royalty rates of 8% in Côte d’Ivoire and 11% (applicable at $4,000 per ounce) in Ghana. Group AISC and has only been calculated based on the three operating mines.
2. Nyanzaga production guidance is based on FID as released in April 2025 – Refer ASX Release – Perseus mining proceeds with development of the Nyanzaga Gold Project. Further guidance for Nyanzaga will be provided in Q3 FY27. All operating costs for Nyanzaga are capitalised until Commercial Production planned for Q4 FY27.

DECEMBER 2026 QUARTER EVENTS & ANNOUNCEMENTS

• 27 October – September 2026 Quarterly Report & Webinar
• 5 November – Macquarie WA Forum
• 9 November – UBS Australasia conference
• 30 November – Annual General Meeting

Competent Person Statement

All production targets referred to in this release are underpinned by estimated Ore Reserves which have been prepared by Competent Persons in accordance with the requirements of the JORC Code.

The information in this report that relates to the Mineral Resources and Ore Reserve was updated by the Company in a market announcement “Perseus Mining updates Mineral Resources and Ore Reserves” released on 26 August 2026. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed.

The Company confirms that the material assumptions underpinning the estimates of Ore Reserves described in “Technical Report — Edikan Gold Mine, Ghana” dated 6 April 2022, “Technical Report — Yaouré Gold Project, Côte d’Ivoire” dated 18 December 2023, “Technical Report — Sissingué Gold Project, Côte d’Ivoire” dated 29 May 2015, and “Technical Report — Nyanzaga Gold Project, Tanzania” dated 10 June 2025 continue to apply.

Caution Regarding Forward Looking Information:

This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company’s publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

This market announcement was authorised for release by Craig Jones, Managing Director and CEO

SX/TSX CODE: PRU CAPITAL STRUCTURE: Ordinary shares: 1,326,111,555 Performance rights: 7,286,920 REGISTERED OFFICE: Level 2 437 Roberts Road Subiaco WA 6008 Telephone: +61 8 6144 1700 www.perseusmining.com

DIRECTORS: Rick Menell Non-Executive Chairman Craig Jones Managing Director & CEO Amber Banfield Non-Executive Director Elissa Cornelius Non-Executive Director Dan Lougher Non-Executive Director John McGloin Non-Executive Director Tommy McKeith Non-Executive Director Jim Rutherford Non-Executive Director

CONTACTS: Craig Jones Managing Director & CEO craig.jones@perseusmining.com Stephen Forman Investor Relations +61 484 036 681 stephen.forman@perseusmining.com Nathan Ryan Media +61 420 582 887 nathan.ryan@nwrcommunications.com.au

Attachment

• TSX PRU Release Sept Q1 FY27

Perth, Western Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) —                                                                     

SEPTEMBER 2026 QUARTER REPORT

Perseus delivers another strong quarter, ending with cash & bullion of US$900 million

Perth, Western Australia/ October 27, 2026/ Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended on September 30, 2026 (the “Quarter”). Below is a summary of the release. The full report is available at www.perseusmining.com www.sedarplus.ca and www.asx.com.au

Overview

• Group TRIFR 1.01 with Nyanzaga Gold Project (NGP) achieving 10.9 million worked hours LTI free
• Q1 FY27 Group production exceeds plan with 92,551 ounces of gold at an All-In Site Costs (AISC) of US$2,035 per ounce
• Average cash margin of US$1,846/oz of gold produced, delivering notional operating cashflow of US$171 million
• Yaouré CMA Underground achieves commercial production
• NGP reached 88.4% overall project progress, and development remains on track for first production by January 2027
• Cash and bullion of US$900 million, plus liquid listed securities valued at US$338 million

FY27 Outlook

With production plans exceeded for Q1 FY27, Perseus remains on track for production and AISC guidance for June 2027 Financial Year (FY27) of 420,000 – 480,000 ounces at US$1,835 – 2,070 per ounce.

Key operating indicators and highlights for the September 2026 quarter (Q1 FY27) include:

Table 1: Group Quarterly Performance

PERFORMANCE INDICATOR	UNIT	DECEMBER 2025 QUARTER	MARCH 2026  QUARTER	JUNE 2026  QUARTER	SEPTEMBER 2026  QUARTER3
Gold recovered	Ounces	88,8881	107,1441	109,0131	92,551
Production Cost	US$/ounce	1,3622	1,2382	1,3402	1,472
All-In Site Cost (AISC)	US$/ounce	1,8002	1,7482	1,9412	2,035
All in Sustaining Cost	US$/ounce	1,8972	1,6042	1,8482	1,855
Gold sales	Ounces	86,6071	96,2601	114,5671	99,661
Average sales price	US$/ounce	3,4372	4,1432	4,0862	3,881
Notional Cashflow	US$ million	1452	2522	2162	171

1. Includes the CMA Underground gold produced and sold for the quarter before commercial production was achieved. Commercial production for CMA Underground was achieved on 1 July 2026.  
2. Excludes CMA Underground production cost, gold produced, AISC, Average sales price and Notional Cashflow as the related cash costs are capitalised until commercial production was achieved.
3. All metrics include CMA Underground following commercial production achieved on 1 July 2026.

Perseus’s Managing Director and CEO Craig Jones said:

“The September Quarter was a solid start to FY27, with all three operations performing and on track for our full year guidance. The CMA Underground has achieved commercial production and our Nyanzaga project is progressing to completion with an outstanding safety record, remaining on budget and on schedule. Our balance sheet remains strong and debt-free, to fund our growth objectives while continuing to deliver meaningful returns to shareholders through our buy-back and the upcoming Special Distribution. I want to thank our employees and contractors for their continued commitment across our sites.

Looking ahead, we expect production to build through the second half of the year as Yaouré’s CMA continues to increase production and Edikan accesses higher grades in the Nkosuo pit along with Nyanzaga commencing operation, positioning Perseus for a transformational year”.

Conference Call Perseus will host investor webinar and conference call to discuss its September 2026 Quarterly Results, at 9.00am AEDT today (27 October 2026). Register for the webinar at:
https://us02web.zoom.us/webinar/register/WN_5JPqtLq5QVOV1wqjG1Mn1g

A recording of the conference call will be made available via Perseus’s website at www.perseusmining.com.

GROUP GOLD PRODUCTION AND COST GUIDANCE

Perseus remains on track to deliver group gold production and AISC for the 2027 financial year as shown in Table 6 below.

Table 6: Production and AISC Guidance

PARAMETER	UNITS	SEPTEMBER 2026  QUARTER (ACTUAL)		2027 FINANCIAL YEAR FORECAST
Yaouré Gold Mine
Production	Ounces		36,648	150,000 – 170,000
All-in Site Cost (1)	US$ per ounce	$	2,393	$1,955 – $2,205
Edikan Gold Mine
Production	Ounces		35,830	150,000 – 170,000
All-in Site Cost (1)	US$ per ounce	$	1,738	$1,700 – $1,920
Sissingué Gold Mine
Production	Ounces		20,073	65,000 – 85,000
All-in Site Cost (1)	US$ per 0unce	$	1,913	$1,865 – $2,105
Nyanzaga Gold Mine
Production (2)	Ounces		–	~55,000
PERSEUS GROUP
Production	Ounces		92,551	420,000 – 480,000
All-in Site Cost (1)	US$ per ounce	$	2,035	$1,835 – $2,070

Notes

1. Cost guidance is based on a gold price assumption of $4,000 per ounce and Government royalty rates of 8% in Côte d’Ivoire and 11% (applicable at $4,000 per ounce) in Ghana. Group AISC and has only been calculated based on the three operating mines.
2. Nyanzaga production guidance is based on FID as released in April 2025 – Refer ASX Release – Perseus mining proceeds with development of the Nyanzaga Gold Project. Further guidance for Nyanzaga will be provided in Q3 FY27. All operating costs for Nyanzaga are capitalised until Commercial Production planned for Q4 FY27.

DECEMBER 2026 QUARTER EVENTS & ANNOUNCEMENTS

• 27 October – September 2026 Quarterly Report & Webinar
• 5 November – Macquarie WA Forum
• 9 November – UBS Australasia conference
• 30 November – Annual General Meeting

Competent Person Statement

All production targets referred to in this release are underpinned by estimated Ore Reserves which have been prepared by Competent Persons in accordance with the requirements of the JORC Code.

The information in this report that relates to the Mineral Resources and Ore Reserve was updated by the Company in a market announcement “Perseus Mining updates Mineral Resources and Ore Reserves” released on 26 August 2026. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed.

The Company confirms that the material assumptions underpinning the estimates of Ore Reserves described in “Technical Report — Edikan Gold Mine, Ghana” dated 6 April 2022, “Technical Report — Yaouré Gold Project, Côte d’Ivoire” dated 18 December 2023, “Technical Report — Sissingué Gold Project, Côte d’Ivoire” dated 29 May 2015, and “Technical Report — Nyanzaga Gold Project, Tanzania” dated 10 June 2025 continue to apply.

Caution Regarding Forward Looking Information:

This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company’s publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

This market announcement was authorised for release by Craig Jones, Managing Director and CEO

SX/TSX CODE: PRU CAPITAL STRUCTURE: Ordinary shares: 1,326,111,555 Performance rights: 7,286,920 REGISTERED OFFICE: Level 2 437 Roberts Road Subiaco WA 6008 Telephone: +61 8 6144 1700 www.perseusmining.com

DIRECTORS: Rick Menell Non-Executive Chairman Craig Jones Managing Director & CEO Amber Banfield Non-Executive Director Elissa Cornelius Non-Executive Director Dan Lougher Non-Executive Director John McGloin Non-Executive Director Tommy McKeith Non-Executive Director Jim Rutherford Non-Executive Director

CONTACTS: Craig Jones Managing Director & CEO craig.jones@perseusmining.com Stephen Forman Investor Relations +61 484 036 681 stephen.forman@perseusmining.com Nathan Ryan Media +61 420 582 887 nathan.ryan@nwrcommunications.com.au

Attachment

• TSX PRU Release Sept Q1 FY27

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Loïc Moreau, Interim CFO

IR@nyxoah.com

Rémi Renard, Head of Investor Relations & Corporate Communication

IR@nyxoah.com

Attachment

• ENGLISH_3Q26_Earnings_Call_Announcement_FINAL

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Loïc Moreau, Interim CFO

IR@nyxoah.com

Rémi Renard, Head of Investor Relations & Corporate Communication

IR@nyxoah.com

Attachment

• ENGLISH_3Q26_Earnings_Call_Announcement_FINAL

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com